EV/Sales Ratio: 9.27x
Is the EV/Sales ratio high or low?
The EV/Sales ratio of 9.27x is 21% below its 5-year average of 11.72x, near the low end of its 5-year range (5.68x–23.94x).
As of Saturday, June 27, 2026. 23.28% above its 12-month average of 7.52x.
TECH EV/Sales Ratio Chart
TECH Average EV/Sales Ratio Chart
TECH Current vs Average EV/Sales Ratio Chart
TECH EV/Sales Ratio Metrics
EV/SALES RATIO
9.27x
EV/SALES RATIO AVG TTM
7.52x
EV/SALES RATIO AVG 3Y
9.16x
EV/SALES RATIO AVG 5Y
10.50x
EV/SALES RATIO AVG 10Y
10.61x
EV/SALES RATIO AVG 15Y
9.75x
EV/SALES RATIO AVG 20Y
9.56x
CURRENT VS TTM AVG
+23.28%
CURRENT VS 3Y AVG
+1.15%
CURRENT VS 5Y AVG
-11.73%
CURRENT VS 10Y AVG
-12.66%
CURRENT VS 15Y AVG
-4.94%
CURRENT VS 20Y AVG
-3.01%
TECH Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Techne Corporation (TECH) | $11.12B | 9.27x | 7.52x | 9.16x | 10.50x |
| Insulet Corp. (PODD)vs › | $10.96B | 3.99x | 7.70x | 8.93x | 12.16x |
| Baxter International Inc. (BAX)vs › | $11.38B | 1.68x | 1.69x | 2.16x | 2.62x |
| Molina Healthcare, Inc. (MOH)vs › | $11.79B | 0.21x | 0.19x | 0.38x | 0.45x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 0.25x | 0.26x | 0.37x | 0.45x |
| Charles River Laboratories International, Inc. (CRL)vs › | $10.20B | 3.30x | 2.81x | 3.02x | 3.76x |
| Tempus AI, Inc. (TEM)vs › | $9.80B | 7.95x | 11.25x | 12.14x | 12.14x |
| Henry Schein, Inc. (HSIC)vs › | $9.68B | 1.01x | 0.94x | 0.94x | 0.95x |
| Revvity, Inc. (RVTY)vs › | $12.61B | 5.21x | 4.79x | 5.55x | 5.57x |
| Align Technology, Inc. (ALGN)vs › | $12.78B | 2.84x | 2.71x | 4.03x | 5.80x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
EV/Sales Ratio FAQ
- What is the EV/Sales ratio for Bio-Techne Corporation (TECH)?
- The EV/Sales ratio for TECH stock is 9.27x.
- Is Bio-Techne Corporation's EV/Sales ratio high or low?
- The EV/Sales ratio of 9.27x is 21% below its 5-year average of 11.72x, near the low end of its 5-year range (5.68x–23.94x).
- What is the TTM average EV/Sales ratio for Bio-Techne Corporation (TECH)?
- The TTM average EV/Sales ratio for TECH stock is 7.52x.
- What is the 3Y average EV/Sales ratio for Bio-Techne Corporation (TECH)?
- The 3Y average EV/Sales ratio for TECH stock is 9.16x.
- What is the 5Y average EV/Sales ratio for Bio-Techne Corporation (TECH)?
- The 5Y average EV/Sales ratio for TECH stock is 10.50x.
- What is the 10Y average EV/Sales ratio for Bio-Techne Corporation (TECH)?
- The 10Y average EV/Sales ratio for TECH stock is 10.61x.
- What is the 15Y average EV/Sales ratio for Bio-Techne Corporation (TECH)?
- The 15Y average EV/Sales ratio for TECH stock is 9.75x.
- What is the 20Y average EV/Sales ratio for Bio-Techne Corporation (TECH)?
- The 20Y average EV/Sales ratio for TECH stock is 9.56x.
TECH EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-26 | 9.27x |
| 2026-06-25 | 9.23x |
| 2026-06-24 | 7.70x |
| 2026-06-23 | 7.36x |
| 2026-06-22 | 7.27x |
| 2026-06-18 | 7.58x |
| 2026-06-17 | 7.20x |
| 2026-06-16 | 7.33x |
| 2026-06-15 | 7.35x |
| 2026-06-12 | 7.07x |
| 2026-06-11 | 7.07x |
| 2026-06-10 | 6.87x |
| 2026-06-09 | 7.12x |
| 2026-06-08 | 6.89x |
| 2026-06-05 | 6.81x |
| 2026-06-04 | 6.96x |
| 2026-06-03 | 6.66x |
| 2026-06-02 | 6.52x |
| 2026-06-01 | 6.65x |
| 2026-05-29 | 6.77x |
| 2026-05-28 | 6.66x |
| 2026-05-27 | 6.30x |
| 2026-05-26 | 6.28x |
| 2026-05-22 | 6.32x |
| 2026-05-21 | 6.21x |
| 2026-05-20 | 6.12x |
| 2026-05-19 | 5.96x |
| 2026-05-18 | 5.83x |
| 2026-05-15 | 5.68x |
| 2026-05-14 | 5.87x |
| 2026-05-13 | 5.89x |
| 2026-05-12 | 6.21x |
| 2026-05-11 | 6.21x |
| 2026-05-08 | 6.33x |
| 2026-05-07 | 6.67x |
| 2026-05-06 | 6.21x |
| 2026-05-05 | 7.47x |
| 2026-05-04 | 7.22x |
| 2026-05-01 | 7.25x |
| 2026-04-30 | 7.29x |
| 2026-04-29 | 6.86x |
| 2026-04-28 | 7.06x |
| 2026-04-27 | 7.26x |
| 2026-04-24 | 7.15x |
| 2026-04-23 | 6.89x |
| 2026-04-22 | 7.71x |
| 2026-04-21 | 7.85x |
| 2026-04-20 | 7.97x |
| 2026-04-17 | 7.80x |
| 2026-04-16 | 7.55x |
| 2026-04-15 | 7.70x |
| 2026-04-14 | 7.72x |
| 2026-04-13 | 7.58x |
| 2026-04-10 | 7.32x |
| 2026-04-09 | 7.32x |
| 2026-04-08 | 7.28x |
| 2026-04-07 | 7.10x |
| 2026-04-06 | 7.10x |
| 2026-04-02 | 7.01x |
| 2026-04-01 | 7.05x |
| 2026-03-31 | 6.90x |
| 2026-03-30 | 6.87x |
| 2026-03-27 | 6.73x |
| 2026-03-26 | 6.95x |
| 2026-03-25 | 6.95x |
| 2026-03-24 | 6.92x |
| 2026-03-23 | 6.86x |
| 2026-03-20 | 6.80x |
| 2026-03-19 | 6.81x |
| 2026-03-18 | 6.71x |
| 2026-03-17 | 6.74x |
| 2026-03-16 | 6.45x |
| 2026-03-13 | 6.71x |
| 2026-03-12 | 6.79x |
| 2026-03-11 | 7.07x |
| 2026-03-10 | 6.97x |
| 2026-03-09 | 7.23x |
| 2026-03-06 | 7.11x |
| 2026-03-05 | 7.36x |
| 2026-03-04 | 7.62x |
| 2026-03-03 | 7.51x |
| 2026-03-02 | 7.61x |
| 2026-02-27 | 7.77x |
| 2026-02-26 | 7.63x |
| 2026-02-25 | 7.62x |
| 2026-02-24 | 7.59x |
| 2026-02-23 | 7.22x |
| 2026-02-20 | 7.58x |
| 2026-02-19 | 7.67x |
| 2026-02-18 | 7.81x |
| 2026-02-17 | 7.70x |
| 2026-02-13 | 7.89x |
| 2026-02-12 | 7.84x |
| 2026-02-11 | 8.34x |
| 2026-02-10 | 8.52x |
| 2026-02-09 | 8.60x |
| 2026-02-06 | 8.77x |
| 2026-02-05 | 8.65x |
| 2026-02-04 | 9.02x |
| 2026-02-03 | 8.51x |
| 2026-02-02 | 8.59x |
| 2026-01-30 | 8.44x |
| 2026-01-29 | 8.43x |
| 2026-01-28 | 8.63x |
| 2026-01-27 | 8.97x |
| 2026-01-26 | 8.90x |
| 2026-01-23 | 8.96x |
| 2026-01-22 | 9.16x |
| 2026-01-21 | 9.38x |
| 2026-01-20 | 9.15x |
| 2026-01-16 | 9.03x |
| 2026-01-15 | 9.20x |
| 2026-01-14 | 9.00x |
| 2026-01-13 | 8.73x |
| 2026-01-12 | 8.76x |
| 2026-01-09 | 8.65x |
| 2026-01-08 | 8.50x |
| 2026-01-07 | 8.56x |
| 2026-01-06 | 8.59x |
| 2026-01-05 | 8.31x |
| 2026-01-02 | 7.87x |
| 2025-12-31 | 7.76x |
| 2025-12-30 | 7.80x |
| 2025-12-29 | 7.82x |
| 2025-12-26 | 7.82x |
| 2025-12-24 | 7.81x |
| 2025-12-23 | 7.82x |
| 2025-12-22 | 7.78x |
| 2025-12-19 | 7.69x |
| 2025-12-18 | 7.54x |
| 2025-12-17 | 7.53x |
| 2025-12-16 | 7.59x |
| 2025-12-15 | 7.75x |
| 2025-12-12 | 7.72x |
| 2025-12-11 | 7.95x |
| 2025-12-10 | 8.02x |
| 2025-12-09 | 7.76x |
| 2025-12-08 | 7.95x |
| 2025-12-05 | 8.13x |
| 2025-12-04 | 8.37x |
| 2025-12-03 | 8.41x |
| 2025-12-02 | 8.29x |
| 2025-12-01 | 8.40x |
| 2025-11-28 | 8.50x |
| 2025-11-26 | 8.51x |
| 2025-11-25 | 8.67x |
| 2025-11-24 | 8.36x |
| 2025-11-21 | 8.11x |
| 2025-11-20 | 7.75x |
| 2025-11-19 | 7.63x |
| 2025-11-18 | 7.68x |
| 2025-11-17 | 7.74x |
| 2025-11-14 | 7.84x |
| 2025-11-13 | 8.01x |
| 2025-11-12 | 8.10x |
| 2025-11-11 | 7.81x |
| 2025-11-10 | 7.59x |
| 2025-11-07 | 7.58x |
| 2025-11-06 | 7.68x |
| 2025-11-05 | 7.91x |
| 2025-11-04 | 8.03x |
| 2025-11-03 | 8.05x |
| 2025-10-31 | 8.22x |
| 2025-10-30 | 8.02x |
| 2025-10-29 | 8.15x |
| 2025-10-28 | 8.40x |
| 2025-10-27 | 8.44x |
| 2025-10-24 | 8.65x |
| 2025-10-23 | 8.67x |
| 2025-10-22 | 8.38x |
| 2025-10-21 | 8.34x |
| 2025-10-20 | 8.22x |
| 2025-10-17 | 8.13x |
| 2025-10-16 | 8.10x |
| 2025-10-15 | 7.84x |
| 2025-10-14 | 7.80x |
| 2025-10-13 | 7.85x |
| 2025-10-10 | 7.72x |
| 2025-10-09 | 7.88x |
| 2025-10-08 | 7.97x |
| 2025-10-07 | 7.79x |
| 2025-10-06 | 8.14x |
| 2025-10-03 | 8.27x |
| 2025-10-02 | 8.16x |
| 2025-10-01 | 7.88x |
| 2025-09-30 | 7.34x |
| 2025-09-29 | 6.90x |
| 2025-09-26 | 6.85x |
| 2025-09-25 | 6.68x |
| 2025-09-24 | 6.77x |
| 2025-09-23 | 6.99x |
| 2025-09-22 | 7.00x |
| 2025-09-19 | 7.02x |
| 2025-09-18 | 7.00x |
| 2025-09-17 | 6.81x |
| 2025-09-16 | 6.84x |
| 2025-09-15 | 6.82x |
| 2025-09-12 | 6.78x |
| 2025-09-11 | 7.03x |
| 2025-09-10 | 6.74x |
| 2025-09-09 | 7.15x |
| 2025-09-08 | 7.14x |
| 2025-09-05 | 7.18x |
| 2025-09-04 | 6.99x |
| 2025-09-03 | 7.04x |
| 2025-09-02 | 7.05x |
| 2025-08-29 | 7.21x |
| 2025-08-28 | 7.17x |
| 2025-08-27 | 7.41x |
| 2025-08-26 | 7.48x |
| 2025-08-25 | 7.47x |
| 2025-08-22 | 7.52x |
| 2025-08-21 | 7.33x |
| 2025-08-20 | 7.38x |
| 2025-08-19 | 7.45x |
| 2025-08-18 | 7.24x |
| 2025-08-15 | 7.28x |
| 2025-08-14 | 7.30x |
| 2025-08-13 | 7.43x |
| 2025-08-12 | 7.18x |
| 2025-08-11 | 6.83x |
| 2025-08-08 | 6.86x |
| 2025-08-07 | 6.83x |
| 2025-08-06 | 6.79x |
| 2025-08-05 | 7.42x |
| 2025-08-04 | 7.45x |
| 2025-08-01 | 7.45x |
| 2025-07-31 | 7.43x |
| 2025-07-30 | 7.82x |
| 2025-07-29 | 7.84x |
| 2025-07-28 | 7.93x |
| 2025-07-25 | 7.96x |
| 2025-07-24 | 7.92x |
| 2025-07-23 | 7.51x |
| 2025-07-22 | 7.22x |
| 2025-07-21 | 6.84x |
| 2025-07-18 | 7.07x |
| 2025-07-17 | 7.24x |
| 2025-07-16 | 7.04x |
| 2025-07-15 | 7.00x |
| 2025-07-14 | 7.15x |
| 2025-07-11 | 7.35x |
| 2025-07-10 | 7.39x |
| 2025-07-09 | 7.15x |
| 2025-07-08 | 7.16x |
| 2025-07-07 | 7.01x |
| 2025-07-03 | 7.22x |
| 2025-07-02 | 7.23x |
| 2025-07-01 | 7.08x |
| 2025-06-30 | 7.00x |
| 2025-06-27 | 7.05x |
| 2025-06-26 | 7.18x |
| 2025-06-25 | 7.06x |
| 2025-06-24 | 6.81x |
| 2025-06-23 | 6.72x |
| 2025-06-20 | 6.79x |
| 2025-06-18 | 6.83x |
| 2025-06-17 | 6.74x |
| 2025-06-16 | 7.02x |
| 2025-06-13 | 6.88x |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kim Kelderman